Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women

Menopause

Volumn 16, Issue 1, 2009, Pages 132-140

  Hedrick, Richard E ^a   Ackerman, Ronald T ^b   Koltun, William D ^c   Halvorsen, Mark B ^d   Lambrecht, Lawrence J ^d  

^a Hawthorne OB/GYN Associates   (United States)

^b Comprehensive Clinical Trials ^*  (United States)

^c Medical Center for Women's Clinical Research   (United States)

^d Upsher Smith Laboratories Inc   (United States)

Author keywords

Estradiol gel; Estrogen therapy; Low dose; Menopause; Transdermal

Indexed keywords

ESTRADIOL; PLACEBO; ESTRONE;

ADULT; AGED; ARTICLE; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LABORATORY TEST; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; POSTMENOPAUSE BLEEDING; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; VAGINA ATROPHY; VAGINA MYCOSIS; VASOMOTOR DISORDER; VULVA ATROPHY; VULVA DISEASE; ADRENERGIC SYSTEM; ATROPHY; BLOOD; GEL; HOT FLUSH; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SWEATING; VAGINA;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ATROPHY; DOUBLE-BLIND METHOD; ESTRADIOL; ESTRONE; FEMALE; GELS; HOT FLASHES; HUMANS; MIDDLE AGED; PATIENT COMPLIANCE; PLACEBOS; POSTMENOPAUSE; SWEATING; VAGINA; VASOMOTOR SYSTEM;

EID: 64049087269     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31817d5372     Document Type: Article

References (40)

1. Birge SJ. The use of estrogen in older women. Clin Geriatr Med 2003;19:617-627.
2. Fraser IS, Mansour D. Delivery systems for hormone replacement therapy. Expert Opin Drug Deliv 2006;3:191-204.
3. Willhite LA, O'Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy 2001;21:464-480.
4. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000;152:463-473.
5. Sikon A, Thacker HL. Treatment options for menopausal hot flashes. Cleve Clin J Med 2004;71:578-582.
6. Grady D. Postmenopausal hormones - therapy for symptoms only. N Engl J Med 2003;348:1835-1837.
7. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
8. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
9. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
10. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363-366.
11. Stephenson J. FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA 2003;289:537-538.
12. North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007;14:168-182.
13. American College of Obstetricians and Gynecologists. Vasomotor symptoms. Obstet Gynecol 2004;104(4 Suppl):S106-S117.
14. Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med 2005;118(Suppl 12B):74-78.
15. Lobo RA. The rationale for low-dose hormonal therapy. Endocrine 2004;24(3):217-221.
16. Simon JA, Ravnikar V. Transdermal estrogen therapy: evidence and update. Female Patient 2007;32:S1-S8.
17. De Aloysio D, Rovati LC, Giacovelli G, Setnikar I, Bottiglioni F. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study. Arzneimittelforschung 2000;50:293-300.
18. Minkin MJ. Considerations in the choice of oral vs. transdermal hormone therapy: a review. J Reprod Med 2004;49:311-320.
19. Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol 2001;184:255-263.
20. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-845.
21. Modena MG, Sismondi P, Mueck AO, et al. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas 2005;52:1-10.
22. AACE Menopause Guidelines Revisions Task Force. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract 2006;12:315-337.
23. Center for Drug Evaluation and Research. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms - recommendations for clinical evaluation. January (draft), Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, 2003.
24. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 1997;314:228-231.
25. Semmens JP, Wagner G. Estrogen deprivation and vaginal function in postmenopausal women. JAMA 1982;248:445-448.
26. Brizzolara S, Killeen J, Severino R. Vaginal pH and parabasal cells in postmenopausal women. Obstet Gynecol 1999;94:700-703.
27. Bachmann GA. The clinical platform for the 17β-estradiol vaginal releasing ring. Am J Obstet Gynecol 1998;178:S257-S260.
28. MacLennan AH. HRT: a reappraisal of the risks and benefits. Med J Aust 2007;186:643-646.
29. Samsioe G. Transdermal hormone therapy: gels and patches. Climacteric 2004;7:347-356.
30. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432.
31. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-625.
32. Warren MP. Historical perspectives in postmenopausal hormone therapy: defining the right dose and duration. Mayo Clin Proc 2007;82:219-226.
33. Cirigliano M. Bioidentical hormone therapy: a review of the evidence. J Womens Health 2007;16:600-631.
34. Jarvinen A, Backstrom A, Elfstrom C, Viitanen A. Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch. Maturitas 2001;38:189-196.
35. Scott RT Jr, Ross B, Anderson C, Archer DF. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 1991;77:758-764.
36. Paoletti AM, Pilia I, Nannipieri F, Bigini C, Melis GB. Comparison of pharmacokinetic profiles of a 17 β-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state. Maturitas 2001;40:203-209.
37. Akhila V, Pratapkumar. A comparison of transdermal and oral HRT for menopausal symptom control. Int J Fertil Womens Med 2006;51:64-69.
38. Hope S, M.C.P.R. Why do British women start and stop hormone replacement therapy? J Br Menopause Soc 1995;1:26-27.
39. Col NF, Pauker SG, Goldberg RJ, et al. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. Arch Intern Med 1999;159:1458-1466.
40. Notelovitz M. Why individualizing hormone therapy is crucial: putting the results of the WHI trial into perspective. Medscape Womens Health 2002;7:9.